ArticleCancers2021

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.

Christine H Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.